Madrigal Pharmaceuticals (MDGL) Cash from Operations (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Cash from Operations of 23329000.0 for Q2 2026, up 149.58% year-over-year from 9347254.25 in Q2 2025, and up 113.93% quarter-over-quarter from 167435000.0 in Q1 2026.
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Cash from Operations (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Cash from Operations for 17 consecutive years, with 23329000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Operations rose 149.58% year-over-year to 23329000.0; the TTM figure through Jun 2026 stood at 197716000.0 (up 35.68% YoY), while the FY2025 annual figure was 189553000.0, up 58.39% from the prior year.
- Cash from Operations advanced to 23329000.0 in Q2 2026 per MDGL's latest filing, from 167435000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 79850000.0 in Q3 2025 and bottomed at 167435000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 74351000.0 across 5 years, with a median of 77621500.0 in 2023.
- Annual changes were most pronounced in 2025 — Cash from Operations jumped 219.21% — and 2026, when it sank 88.36%.
- Madrigal Pharmaceuticals' Cash from Operations stood at 58515000.0 in 2022, then sank by 36.6% to 79933000.0 in 2023, then sank by 30.72% to 104486000.0 in 2024, then declined by 27.73% to 133460000.0 in 2025, then jumped by 117.48% to 23329000.0 in 2026.
- Business Quant data shows MDGL's Cash from Operations at 23329000.0 in Q2 2026, 167435000.0 in Q1 2026, and 133460000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Madrigal Pharmaceuticals | 15.79 Bn | 14.96 Bn | - | 23.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 23.33 Mn |
| Mar 31, 2026 | -167.44 Mn |
| Dec 31, 2025 | -133.46 Mn |
| Sep 30, 2025 | 79.85 Mn |
| Jun 30, 2025 | -47.05 Mn |
| Mar 31, 2025 | -88.89 Mn |
| Dec 31, 2024 | -104.49 Mn |
| Sep 30, 2024 | -66.98 Mn |
| Jun 30, 2024 | -134.95 Mn |
| Mar 31, 2024 | -149.16 Mn |
| Dec 31, 2023 | -79.93 Mn |
| Sep 30, 2023 | -84.92 Mn |
| Jun 30, 2023 | -75.31 Mn |
| Mar 31, 2023 | -84.07 Mn |
| Dec 31, 2022 | -58.52 Mn |
| Sep 30, 2022 | -59.07 Mn |
| Jun 30, 2022 | -57.36 Mn |
| Mar 31, 2022 | -49.91 Mn |
| Dec 31, 2021 | -48.05 Mn |
| Sep 30, 2021 | -45.56 Mn |